Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 141

1.

Mutations in CBL occur frequently in juvenile myelomonocytic leukemia.

Loh ML, Sakai DS, Flotho C, Kang M, Fliegauf M, Archambeault S, Mullighan CG, Chen L, Bergstraesser E, Bueso-Ramos CE, Emanuel PD, Hasle H, Issa JP, van den Heuvel-Eibrink MM, Locatelli F, Stary J, Trebo M, Wlodarski M, Zecca M, Shannon KM, Niemeyer CM.

Blood. 2009 Aug 27;114(9):1859-63. doi: 10.1182/blood-2009-01-198416. Epub 2009 Jul 1.

PMID:
19571318
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Mutations of an E3 ubiquitin ligase c-Cbl but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia.

Muramatsu H, Makishima H, Jankowska AM, Cazzolli H, O'Keefe C, Yoshida N, Xu Y, Nishio N, Hama A, Yagasaki H, Takahashi Y, Kato K, Manabe A, Kojima S, Maciejewski JP.

Blood. 2010 Mar 11;115(10):1969-75. doi: 10.1182/blood-2009-06-226340. Epub 2009 Dec 11.

PMID:
20008299
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Gene mutations in the Ras pathway and the prognostic implication in Korean patients with juvenile myelomonocytic leukemia.

Park HD, Lee SH, Sung KW, Koo HH, Jung NG, Cho B, Kim HK, Park IA, Lee KO, Ki CS, Kim SH, Yoo KH, Kim HJ.

Ann Hematol. 2012 Apr;91(4):511-7. doi: 10.1007/s00277-011-1326-9. Epub 2011 Sep 8.

PMID:
21901340
[PubMed - indexed for MEDLINE]
4.

Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia.

Niemeyer CM, Kang MW, Shin DH, Furlan I, Erlacher M, Bunin NJ, Bunda S, Finklestein JZ, Sakamoto KM, Gorr TA, Mehta P, Schmid I, Kropshofer G, Corbacioglu S, Lang PJ, Klein C, Schlegel PG, Heinzmann A, Schneider M, Starý J, van den Heuvel-Eibrink MM, Hasle H, Locatelli F, Sakai D, Archambeault S, Chen L, Russell RC, Sybingco SS, Ohh M, Braun BS, Flotho C, Loh ML.

Nat Genet. 2010 Sep;42(9):794-800. doi: 10.1038/ng.641. Epub 2010 Aug 8.

PMID:
20694012
[PubMed - indexed for MEDLINE]
5.

Spectrum of molecular defects in juvenile myelomonocytic leukaemia includes ASXL1 mutations.

Sugimoto Y, Muramatsu H, Makishima H, Prince C, Jankowska AM, Yoshida N, Xu Y, Nishio N, Hama A, Yagasaki H, Takahashi Y, Kato K, Manabe A, Kojima S, Maciejewski JP.

Br J Haematol. 2010 Jul;150(1):83-7. doi: 10.1111/j.1365-2141.2010.08196.x. Epub 2010 Apr 12.

PMID:
20408841
[PubMed - indexed for MEDLINE]
6.

Genetic typing of CBL, ASXL1, RUNX1, TET2 and JAK2 in juvenile myelomonocytic leukaemia reveals a genetic profile distinct from chronic myelomonocytic leukaemia.

Pérez B, Kosmider O, Cassinat B, Renneville A, Lachenaud J, Kaltenbach S, Bertrand Y, Baruchel A, Chomienne C, Fontenay M, Preudhomme C, Cavé H.

Br J Haematol. 2010 Dec;151(5):460-8. doi: 10.1111/j.1365-2141.2010.08393.x. Epub 2010 Oct 19.

PMID:
20955399
[PubMed - indexed for MEDLINE]
7.

Germline mutations of the CBL gene define a new genetic syndrome with predisposition to juvenile myelomonocytic leukaemia.

Pérez B, Mechinaud F, Galambrun C, Ben Romdhane N, Isidor B, Philip N, Derain-Court J, Cassinat B, Lachenaud J, Kaltenbach S, Salmon A, Désirée C, Pereira S, Menot ML, Royer N, Fenneteau O, Baruchel A, Chomienne C, Verloes A, Cavé H.

J Med Genet. 2010 Oct;47(10):686-91. doi: 10.1136/jmg.2010.076836. Epub 2010 Jun 12.

PMID:
20543203
[PubMed - indexed for MEDLINE]
8.

Somatic mosaicism for oncogenic NRAS mutations in juvenile myelomonocytic leukemia.

Doisaki S, Muramatsu H, Shimada A, Takahashi Y, Mori-Ezaki M, Sato M, Kawaguchi H, Kinoshita A, Sotomatsu M, Hayashi Y, Furukawa-Hibi Y, Yamada K, Hoshino H, Kiyoi H, Yoshida N, Sakaguchi H, Narita A, Wang X, Ismael O, Xu Y, Nishio N, Tanaka M, Hama A, Koike K, Kojima S.

Blood. 2012 Aug 16;120(7):1485-8. doi: 10.1182/blood-2012-02-406090. Epub 2012 Jul 2.

PMID:
22753870
[PubMed - indexed for MEDLINE]
Free Article
9.

CBL linker region and RING finger mutations lead to enhanced granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling via elevated levels of JAK2 and LYN.

Javadi M, Richmond TD, Huang K, Barber DL.

J Biol Chem. 2013 Jul 5;288(27):19459-70. doi: 10.1074/jbc.M113.475087. Epub 2013 May 21.

PMID:
23696637
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

[Juvenile myelomonocytic leukemias].

Lachenaud J, Strullu M, Baruchel A, Cavé H.

Bull Cancer. 2014 Mar;101(3):302-13. doi: 10.1684/bdc.2014.1908. Review. French.

PMID:
24691193
[PubMed - indexed for MEDLINE]
11.

Current management of juvenile myelomonocytic leukemia and the impact of RAS mutations.

Yoshida N, Doisaki S, Kojima S.

Paediatr Drugs. 2012 Jun 1;14(3):157-63. doi: 10.2165/11631360-000000000-00000. Review.

PMID:
22480363
[PubMed - indexed for MEDLINE]
12.

Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia.

Sakaguchi H, Okuno Y, Muramatsu H, Yoshida K, Shiraishi Y, Takahashi M, Kon A, Sanada M, Chiba K, Tanaka H, Makishima H, Wang X, Xu Y, Doisaki S, Hama A, Nakanishi K, Takahashi Y, Yoshida N, Maciejewski JP, Miyano S, Ogawa S, Kojima S.

Nat Genet. 2013 Aug;45(8):937-41. doi: 10.1038/ng.2698. Epub 2013 Jul 7.

PMID:
23832011
[PubMed - indexed for MEDLINE]
13.

Correlation of clinical features with the mutational status of GM-CSF signaling pathway-related genes in juvenile myelomonocytic leukemia.

Yoshida N, Yagasaki H, Xu Y, Matsuda K, Yoshimi A, Takahashi Y, Hama A, Nishio N, Muramatsu H, Watanabe N, Matsumoto K, Kato K, Ueyama J, Inada H, Goto H, Yabe M, Kudo K, Mimaya J, Kikuchi A, Manabe A, Koike K, Kojima S.

Pediatr Res. 2009 Mar;65(3):334-40. doi: 10.1203/PDR.0b013e3181961d2a.

PMID:
19047918
[PubMed - indexed for MEDLINE]
14.

Childhood myelodysplastic syndrome: focus on the approach to diagnosis and treatment of juvenile myelomonocytic leukemia.

Loh ML.

Hematology Am Soc Hematol Educ Program. 2010;2010:357-62. doi: 10.1182/asheducation-2010.1.357. Review.

PMID:
21239819
[PubMed - indexed for MEDLINE]
Free Article
15.

Mitotic recombination and compound-heterozygous mutations are predominant NF1-inactivating mechanisms in children with juvenile myelomonocytic leukemia and neurofibromatosis type 1.

Steinemann D, Arning L, Praulich I, Stuhrmann M, Hasle H, Stary J, Schlegelberger B, Niemeyer CM, Flotho C.

Haematologica. 2010 Feb;95(2):320-3. doi: 10.3324/haematol.2009.010355. Epub 2009 Dec 16.

PMID:
20015894
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

The strange case of the lost NRAS mutation in a child with juvenile myelomonocytic leukemia.

De Filippi P, Zecca M, Novara F, Lisini D, Maserati E, Pasquali F, Rosti V, Carlo-Stella C, Zavras N, Cagioni C, Zuffardi O, Pagliara D, Danesino C, Locatelli F.

Pediatr Blood Cancer. 2012 Sep;59(3):580-2. doi: 10.1002/pbc.23401. Epub 2011 Dec 19.

PMID:
22183880
[PubMed - indexed for MEDLINE]
17.

Genome-wide single-nucleotide polymorphism analysis in juvenile myelomonocytic leukemia identifies uniparental disomy surrounding the NF1 locus in cases associated with neurofibromatosis but not in cases with mutant RAS or PTPN11.

Flotho C, Steinemann D, Mullighan CG, Neale G, Mayer K, Kratz CP, Schlegelberger B, Downing JR, Niemeyer CM.

Oncogene. 2007 Aug 23;26(39):5816-21. Epub 2007 Mar 12.

PMID:
17353900
[PubMed - indexed for MEDLINE]
18.

Recent advances in the pathogenesis and management of juvenile myelomonocytic leukaemia.

Koike K, Matsuda K.

Br J Haematol. 2008 May;141(5):567-75. doi: 10.1111/j.1365-2141.2008.07104.x. Epub 2008 Apr 13. Review.

PMID:
18422786
[PubMed - indexed for MEDLINE]
19.

Long-term survival after nonintensive chemotherapy in some juvenile myelomonocytic leukemia patients with CBL mutations, and the possible presence of healthy persons with the mutations.

Matsuda K, Taira C, Sakashita K, Saito S, Tanaka-Yanagisawa M, Yanagisawa R, Nakazawa Y, Shiohara M, Fukushima K, Oda M, Honda T, Nakahata T, Koike K.

Blood. 2010 Jul 1;115(26):5429-31. doi: 10.1182/blood-2009-12-260729. No abstract available.

PMID:
20595524
[PubMed - indexed for MEDLINE]
Free Article
20.

Determination of Ras-GTP and Ras-GDP in patients with acute myelogenous leukemia (AML), myeloproliferative syndrome (MPS), juvenile myelomonocytic leukemia (JMML), acute lymphocytic leukemia (ALL), and malignant lymphoma: assessment of mutational and indirect activation.

Raepple D, von Lintig F, Zemojtel T, Duchniewicz M, Jung A, Lübbert M, Boss GR, Scheele JS.

Ann Hematol. 2009 Apr;88(4):319-24. doi: 10.1007/s00277-008-0593-6. Epub 2008 Sep 11.

PMID:
18784923
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk